Starfish Medical Client, Pyng Medical Corp., announces the release of FASTResponder(TM)

June 27, 2013  Vancouver, B.C. – Pyng Medical Corp. (PYT:TSX.V) (the “Company”) today announced that FASTResponder™, the company’s next generation Intraosseus Infusion device, has received the CE Mark in Europe and has been cleared by the United States Food and Drug Administration (FDA) for marketing in the United States.

The FASTResponder™ product has received initial positive input from medical professionals regarding it being easy to learn and easy to use. Such feedback indicates the possibility of opening up usage of Pyng Intraosseus Infusion products to a wider range of applications and markets. This expansion of market opportunity is anticipated to enhance company sales potential moving forward and the company will now increase marketing activity in an attempt to capture this opportunity.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng’s expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

More information about the Company is available on SEDAR at under the Company’s profile and on its website:

For More Information

George Dorin Chief Financial Officer Pyng Medical Corp. (604) 303-7964 x219

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management’s expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company’s strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like “expects”, “anticipates”, “plans”, “intends”, “projects”, “indicates”, and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.


Join over 6000 medical device professionals who receive our engineering, regulatory and commercialization insights and tips every month.